Clinical Trials Logo

Colorectal Cancer clinical trials

View clinical trials related to Colorectal Cancer.

Filter by:

NCT ID: NCT05693519 Active, not recruiting - Colorectal Cancer Clinical Trials

GastroIntestinal Cancer in Children and Adolescents

GICCA
Start date: December 22, 2022
Phase:
Study type: Observational

The goal of this observational population-based cohort study is to investigate the clinical characteristics and outcomes of children and adolescents with primary gastrointestinal malignancies registered in the publicly available Surveillance, Epidemiology, and End Results (SEER) 17 database during 2000-2019.

NCT ID: NCT05692024 Not yet recruiting - Colorectal Cancer Clinical Trials

COffee and Metabolites Modulating the Gut MicrobiomE in coloN canCER

COMMENCER
Start date: June 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is research study is assessing the effects of 6-g daily use of freeze-dried instant coffee on liver fat and fibrosis and the gut microbiome and metabolome in patients who have undergone surgery for stage I or II colon cancer or undergone surgery and completed chemotherapy for stage III colon cancer.

NCT ID: NCT05686122 Not yet recruiting - Colorectal Cancer Clinical Trials

Initial Testing of a Mobile App Pain Coping Intervention for Outpatient Oncology Settings (PainPac)

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

PainPac is innovative in its potential to integrate with healthcare systems through electronic medical records (EMRs). PainPac leverages technology to increase patient access to interventions and uses real-time assessment to improve care. PainPac is positioned to rapidly provide improved care through combining biological data (e.g., EMRs, patient collected) with behavioral data to dramatically improve outcomes. PainPac could track beneficial outcomes related to clinical pain scores (e.g., patients with scores 4-8 benefit) and intervention implementation could be based on this; a more advanced possibility is use of geospatial tracking to predict space/time where pain is likely to impact functioning and push an intervention strategy - behavioral or pharmacological. PainPac is designed for future transmission of data to EMRs to inform providers of patient status. This work will provide data to bypass traditional efficacy trials and move quickly to a large effectiveness trial.

NCT ID: NCT05684211 Not yet recruiting - Colorectal Cancer Clinical Trials

A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer

Start date: January 2023
Phase: Phase 2
Study type: Interventional

This is a multicenter, open-label, parallel-group, randomised, A phase IIb clinical trial of efficacy and safety of Ametumumab in combination with anti-PD-1 monoclonal antibody and FOLFIRI versus Ametumumab or Cetuximab in combination with FOLFIRI in patients with RAS wild-type advanced colorectal cancer.

NCT ID: NCT05683418 Not yet recruiting - Colorectal Cancer Clinical Trials

A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors

Start date: February 2023
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to evaluate the safety of TOS-358 in adults with select solid tumors who meet study enrollment criteria. The main questions it aims to answer are: 1. what is the maximum tolerated dose and recommended dose for phase 2? 2. how safe and tolerable is TOS-358 at different dose levels when taken orally once or twice per day?

NCT ID: NCT05682898 Not yet recruiting - Colorectal Cancer Clinical Trials

Perioperative Management of Colorectal Cancer Patients Infected With COVID-19: a Multicenter Prospective Cohort Study.

Start date: January 15, 2023
Phase:
Study type: Observational

This trial is a multicenter prospective cohort study to explore timing of colorectal cancer surgery after COVID-19 infection so that can assist clinicians and patients. Currently, there is less evidence on perioperative outcomes after COVID-19 vaccination and the omicron variant. Therefore, it is necessary to update previously published consensus which recommends that patients should avoid elective surgery within 7 weeks of COVID-19 infection remain, unless the benefits of doing so exceed the risk of waiting. Aiming at the above problems, we plan to carry out a multicenter prospective cohort study to develop perioperative management according patients' different conditions.

NCT ID: NCT05678257 Recruiting - Colorectal Cancer Clinical Trials

A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer

Start date: January 2023
Phase: Phase 2
Study type: Interventional

This is a randomized, open-label, dose/schedule optimization study comparing NUC-3373/leucovorin (LV)/irinotecan plus bevacizumab (NUFIRI-bev) to 5-FU/LV/irinotecan plus bevacizumab (FOLFIRI-bev) for the treatment of patients with unresectable metastatic colorectal cancer. A total of 171 patients will be randomized 1:1:1 to either NUFIRI-bev on a weekly NUC-3373 schedule, NUFIRI-bev based on an alternate weekly NUC-3373 schedule, or FOLFIRI bev on an alternate weekly schedule. The main objectives are to assess and compare the efficacy and safety of the 3 regimens. Pharmacokinetics will be assessed on the 2 NUFIRI arms.

NCT ID: NCT05677958 Completed - Colorectal Cancer Clinical Trials

Protein Intake in Patients With Colorectal or Lung Cancer When Receiving a Nutritional Supplement

PROTEOS
Start date: January 17, 2019
Phase: N/A
Study type: Interventional

The PROTEOS study is an randomized controlled, open label, parallel-group, multi-centre and multicounty interventional study to assess the acceptance and implementation of Compact Protein, a low volume, energy dense and high protein oral nutritional support in clinical practice according to the ESPEN guidelines in colorectal and lung cancer patients undergoing chemo(radio)- or immunotherapy treatment.

NCT ID: NCT05677113 Not yet recruiting - Colorectal Cancer Clinical Trials

A Study of QBECO Versus Placebo in the Treatment of Colorectal Cancer That Has Spread to the Liver

PERIOP-06
Start date: March 1, 2023
Phase: Phase 2
Study type: Interventional

The goal of this type of clinical trial is t to answer the following question: Can the chance of colorectal cancer progressing be lowered by taking a medication, QBECO, before and after surgery? The goal of this study is to find out if this approach is better or worse than the standard of care for your type of cancer. The standard of care is defined as care most people get for metastatic colorectal cancer. There is currently no standard of care drug being given before or after surgery to prevent further spread of your cancer. Participants will be asked to self-inject the study medication before surgery for minimum of 11 days and after surgery for minimum of 41 days. Participants will be followed up every 3 months for 2 years, with a final visit at year 5.

NCT ID: NCT05676190 Recruiting - Colorectal Cancer Clinical Trials

Clinical Study on the Efficacy of Autologous Cell Factor Induced Killer Cells in the Treatment of Colorectal Cancer

Start date: January 9, 2023
Phase: N/A
Study type: Interventional

This project plans to use CIK combined with chemotherapy, immunotherapy and targeted therapy to treat CRC patients, so as to explore the effectiveness of CIK treatment and the CRC subtypes more suitable for CIK treatment, thereby improving the survival rate and quality of life of CRC patients.